<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939324</url>
  </required_header>
  <id_info>
    <org_study_id>87RI20-0067 (ExOnSite-Pro)</org_study_id>
    <nct_id>NCT04939324</nct_id>
  </id_info>
  <brief_title>Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer</brief_title>
  <acronym>ExOnSite-Pro</acronym>
  <official_title>Analyse du Profil moléculaire Des Exosomes de la Veine Pulmonaire Dans le Cancer Bronchique de Stade précoce</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational prospective single-center study of 30 patients operated for&#xD;
      early-staged non-small cell lung cancer. The main aim is the analysis of molecular profiling&#xD;
      of exosome with a sample in tumor-draining vein in order to identify prognostic molecular&#xD;
      characteristics associated with cancer recurrence after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgical resection remains the best chance for cure in patients with early-stage&#xD;
      non-small-cell lung cancer (NSCLC). Unfortunately, approximately 30-50% of patients will&#xD;
      relapse within 5-year of curative surgery despite early TNM-stage. The Identification of&#xD;
      prognostic biomarkers of relapse is a necessity. Among them, extracellular vesicles&#xD;
      (exosomes) study seems promising in early stage cancers and samples directly in&#xD;
      tumor-draining vein to. The pulmonary vein is draining blood directly from the lungs and&#xD;
      sampling at this location could provide a higher yield for oncosome. The litterature reports&#xD;
      that Navarro et al. are the only team to have link exosome characteristics to oncological&#xD;
      outcomes following surgery. The investigators propose to analyze the molecular profiling&#xD;
      mediated by these extracellular vesicles in the tumor-draining vein of operated patients.&#xD;
&#xD;
      A peripheral blood sample is recolted before surgery (D-1 or D0). During oncological lung&#xD;
      surgery, the pulmonary tumor-drainage vein is first exposed and punctured with a needle prior&#xD;
      to subsequent surgical manipulation for resection (D0). A piece of resected tumor will be&#xD;
      analyzed for the study (D0). Quantification and size distribution of exosome and molecular&#xD;
      cargo of exosome in blood samples (peripheral and pulmonary vein) and tumor are analyzed (DNA&#xD;
      sequencing).&#xD;
&#xD;
      Standard clinical and radiological follow-up is then performed and 2-year overall survival&#xD;
      and 2-year disease free-survival are checked.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">August 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate size distribution, concentration and molecular profiling of pulmonary vein exosomes at inclusion</measure>
    <time_frame>36 months</time_frame>
    <description>Concentration of extracellular vesicule (million of particule/mL of blood)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size distribution, molecular profiling of peripheral vein exosome sat inclusion</measure>
    <time_frame>36 months</time_frame>
    <description>The size distribution of extracellular vesicules harvested</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutations and polymorphism in resected lung cancer</measure>
    <time_frame>36 months</time_frame>
    <description>Analyze of the molecular profile in the resected tumor tissus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>36 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two-year disease-free survival</measure>
    <time_frame>24 months</time_frame>
    <description>Two-year disease-free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Exosomes</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Blood samples at 2 sites: peripheral vein and tumor-draining vein</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>D0: surgery (inclusion): oncological lung resection&#xD;
Blood samples at 2 sites: peripheral vein and tumor-draining vein&#xD;
Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples at 2 sites: peripheral vein and tumor-draining vein</intervention_name>
    <description>D0: surgery (inclusion): oncological lung resection&#xD;
Blood samples at 2 sites: peripheral vein and tumor-draining vein&#xD;
Resected tumor analysis Standard clinical and radiological follow-up during 2 years (medical consultation or phone call)</description>
    <arm_group_label>Blood samples at 2 sites: peripheral vein and tumor-draining vein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Surgical non-small cell lung cancer with pure solid nodule or part-solid ground glass&#xD;
        nodule on CT-scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pure ground glass nodule,&#xD;
&#xD;
          -  Neoadjuvant therapy,&#xD;
&#xD;
          -  Second cancer or cancer in the 5 years,&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Patients &lt;18 years-old,&#xD;
&#xD;
          -  Tutorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérémy Tricard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jérémy Tricard, MD</last_name>
    <phone>0033555058616</phone>
    <email>jeremy.tricard@chu-limoges.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fabrice Lalloué, PhD</last_name>
    <phone>0033555457231</phone>
    <email>fabrice.lalloue@unilim.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérémy Tricard, MD</last_name>
      <phone>0033555058616</phone>
      <email>jeremy.tricard@chu-limoges.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

